CSPC Pharmaceutical Group Receives Approval for Clevidipine Injectable Emulsion
I'm PortAI, I can summarize articles.
CSPC Pharmaceutical Group Limited has received drug registration approval from China's National Medical Products Administration for its Clevidipine Injectable Emulsion, indicated for hypertension treatment when oral therapy is not feasible. The product offers rapid action, requires no dose adjustment for hepatic or renal dysfunction, and can be administered without dilution, making it suitable for patients at risk of fluid overload. This approval is expected to enhance the company's cardiovascular product pipeline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments